These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7473081)

  • 1. Measuring switchability and prescribability: when is average bioequivalence sufficient?
    Hauck WW; Anderson S
    J Pharmacokinet Biopharm; 1994 Dec; 22(6):551-64. PubMed ID: 7473081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New bioequivalence studies: individual bioequivalence and population bioequivalence.
    Nakai K; Fujita M; Ogata H
    Yakugaku Zasshi; 2000 Nov; 120(11):1201-8. PubMed ID: 11190205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generic products of antiepileptic drugs (AEDs): is it an issue?
    Bialer M
    Epilepsia; 2007 Oct; 48(10):1825-32. PubMed ID: 17850324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An individual bioequivalence criterion: regulatory considerations.
    Chen ML; Patnaik R; Hauck WW; Schuirmann DJ; Hyslop T; Williams R
    Stat Med; 2000 Oct; 19(20):2821-42. PubMed ID: 11033578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PhRMA perspective on population and individual bioequivalence.
    Barrett JS; Batra V; Chow A; Cook J; Gould AL; Heller AH; Lo MW; Patterson SD; Smith BP; Stritar JA; Vega JM; Zariffa N
    J Clin Pharmacol; 2000 Jun; 40(6):561-70. PubMed ID: 10868305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Types of bioequivalence and related statistical considerations.
    Hauck WW; Anderson S
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):181-7. PubMed ID: 1592546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescribability and switchability of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    J Control Release; 1999 Nov; 62(1-2):33-40. PubMed ID: 10518632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Regulatory Standpoint on Evaluating the Bioequivalence of Different Classes of Generic Drugs - Is the Evaluation in the Right Direction?
    Micheal F; Sayana M; Motial BM
    Curr Drug Metab; 2019; 20(10):835-844. PubMed ID: 31589117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On TIER method for assessment of individual bioequivalence.
    Ju HL
    J Biopharm Stat; 1997 Mar; 7(1):63-85. PubMed ID: 9056589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tests for individual and population bioequivalence based on generalized p-values.
    McNally RJ; Iyer H; Mathew T
    Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kullback-Leibler divergence for evaluating bioequivalence.
    Dragalin V; Fedorov V; Patterson S; Jones B
    Stat Med; 2003 Mar; 22(6):913-30. PubMed ID: 12627409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On safety margin for drug interchangeability.
    Zheng J; Chow SC; Song F
    J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On population and individual bioequivalence.
    Schall R; Luus HG
    Stat Med; 1993 Jun; 12(12):1109-24. PubMed ID: 8210816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global Harmonization of Comparator Products for Bioequivalence Studies.
    Gwaza L; Gordon J; Leufkens H; Stahl M; García-Arieta A
    AAPS J; 2017 May; 19(3):603-606. PubMed ID: 28265983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extension to the use of tolerance intervals for the assessment of individual bioequivalence.
    Esinhart JD; Chinchilli VM
    J Biopharm Stat; 1994 Mar; 4(1):39-52. PubMed ID: 8019583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing bioequivalence and drug interchangeability.
    Chen M; Chow SC
    J Biopharm Stat; 2017; 27(2):272-281. PubMed ID: 27936343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A small sample confidence interval approach to assess individual bioequivalence.
    Hyslop T; Hsuan F; Holder DJ
    Stat Med; 2000 Oct; 19(20):2885-97. PubMed ID: 11033583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual bioequivalence testing under 2x3 designs.
    Chow SC; Shao J; Wang H
    Stat Med; 2002 Mar; 21(5):629-48. PubMed ID: 11870806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.